Clinical Trials Logo

Lymphoma, Extranodal NK-T-Cell clinical trials

View clinical trials related to Lymphoma, Extranodal NK-T-Cell.

Filter by:

NCT ID: NCT03630731 Recruiting - Clinical trials for Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Start date: August 2018
Phase: Phase 2
Study type: Interventional

Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only 55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained complete or partial remission had much favourable duration of remission. Thus, the invesgator design this study to evaluate the role of maintenance treatment of chidamide for induction chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.

NCT ID: NCT03154918 Recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

NCT ID: NCT02859402 Recruiting - Clinical trials for T-cell Non-Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

RRTCLAlloSCT
Start date: December 2016
Phase: Phase 2
Study type: Interventional

Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.

NCT ID: NCT02742727 Recruiting - Clinical trials for Acute Myeloid Leukemia

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02560441 Recruiting - Clinical trials for Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Start date: September 2015
Phase: Phase 2
Study type: Interventional

The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both arms are 3 cycles. And the chemotherapy is repeated every 3 weeks.. The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is repeated every 3 weeks.

NCT ID: NCT02544425 Recruiting - Clinical trials for Extranodal NK-T-Cell Lymphoma

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

VIDL+ASCT
Start date: February 21, 2016
Phase: Phase 2
Study type: Interventional

Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in patients with stage III/IV extranodal NK/T-cell Lymphoma.

NCT ID: NCT02085655 Recruiting - Clinical trials for Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Start date: April 25, 2013
Phase: Phase 3
Study type: Interventional

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

NCT ID: NCT02080234 Recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Start date: March 2014
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of first-line gemcitabine, oxaliplatin, and asparaginase (GELOX) with concurrent involved-field radiation therapy for patients in newly diagnosed stage IE/IIE ENKTL.

NCT ID: NCT01933282 Recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

MESA Treatment for NK/T Cell Lymphoma

MTN
Start date: January 2013
Phase: Phase 2
Study type: Interventional

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma

NCT ID: NCT01921790 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Start date: August 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of avastin combined with gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line treatment in patients with untreated natural killer(NK)/T cell lymphoma